The Asia-Pacific cell therapy market growth is anticipated to progress at a CAGR of 15.16% during the forecast period, 2022-2030, and is expected to reach a revenue of $1074.70 million by 2030.

ASIA-PACIFIC CELL THERAPY MARKET FORECAST 2022-2030

Asia-Pacific Cell Therapy Market by Cell Type (Stem Cell (Bone Marrow, Blood, Umbilical Cord-derived Stem Cell, Adipose-derived Stem Cell, Others), Non-stem Cell) Market by Therapy Type (Autologous, Allogeneic) Market by Therapeutic Application (Malignancies, Musculoskeletal Disorders, Autoimmune Disorders, Dermatology, Other Applications) Market by End-user (Hospitals & Clinics, Academic & Research Institutes) By Geography

Request free sample

The Asia-Pacific cell therapy market growth is anticipated to progress at a CAGR of 15.16% during the forecast period, 2022-2030, and is expected to reach a revenue of $1074.70 million by 2030.

The cell therapy market growth in Asia-Pacific is attributed to the progress made in stem cell treatment in several Asian countries. Also, Asia is at the forefront of stem cell research. In addition, many stem cell consortiums exist in Asian nations that provide concentrated and coordinated R&D efforts.

Besides, there is growing migration of patients from western countries, accredited to the flexible legal framework. Moreover, global companies are entering the industry, given the region’s large population base and unexplored potential. However, Asia-Pacific cell therapy market growth is hampered by high costs.

Asia-Pacific Cell Therapy Market

To know more about this report, request a free sample copy

The Asia-Pacific cell therapy market growth analysis includes the assessment of Singapore, Thailand, Japan, China, India, Australia & New Zealand, Singapore, and Rest of Asia-Pacific.

According to Nature, a leading multidisciplinary science journal, CAR T-cell therapy clinical trials make up over 50% of all cell and gene therapy studies in China. Also, around 200 CAR-T studies are being conducted, encompassing various indications and targets from hematology-oncology to solid tumors. In addition, China has established itself as a global leader in cell and gene therapy (CGT) development, ranking second globally, with more than 1000 clinical trials either in progress or completed. This is majorly attributed to the country’s robust policy backing. Besides, China has a flourishing cell and gene therapy biotech industry, headed by over 45 local companies and four partnerships with international partners with CGT pipelines for investigational new drugs (INDs).

Furthermore, there have been significant developments in CGT as part of the new wave of advanced therapy medicinal products (ATMP) that offers patients with new hope. Additionally, the government published a number of progressive policies between 2018 and 2019 under the direction of the National Health Commission (NHC) and the National Medical Products Administration (NMPA) to strengthen regulations in the CGT industry. Such developments have facilitated a transparent framework that healthcare organizations and R&D-stage companies use to get regulatory licenses for CGT therapies. These factors drive the cell therapy market growth in China.

The Asia-Pacific cell therapy market segmentation includes the analysis of therapeutic application, end-user, therapy type, and cell type. The end-user segment includes academic & research institutes and hospitals & clinics.

With regard to academic & research institutes, the ongoing research for cancer and the rising investments in R&D through public and private partnerships are projected to boost the segment’s growth. For instance, panCella, an early-stage biotechnology company, received approximately $305078.5 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) for the R&D of its technology platforms used for cell therapy. Such investments are projected to raise the demand for instruments to conduct research for cell therapies.

For instance, the Oxford Stem Cell Institute (OSCI), a division of Oxford University, encompasses 45 core and associated laboratories spread out over Oxford. They aim to create more potent stem cell and anti-cancer therapies backed by a diverse group of experts. In addition, more than 1000 scientists work at the Harvard Stem Cell Institute (HSCI), which boasts the world’s concentration of biomedical researchers. Their objective is to accelerate the delivery of stem cell-based therapies to patients.

Some of the leading companies in the Asia-Pacific cell therapy market include JCR Pharmaceuticals Co Ltd, Mesoblast Limited, Kolon TissueGene Inc, MEDIPOST Co Ltd, etc.

JCR Pharmaceuticals specializes in the development of pharmaceutical products and is engaged in the research & discovery of therapeutic drugs for lysosomal storage diseases. It is headquartered in Ashiya, Japan.

One of its key products, TEMCELL®HS Inj, is a Mesenchymal Stem Cell (MSC)-based allogeneic regenerative medical product designed for treating acute Graft-Versus-Host Disease (acute GvHD).

Report Synopsis

Report ScopeDetails
Market Forecast Years2022-2030
Base Year2021
Market Historical Years2018-2021
Forecast UnitsRevenue ($ Million)
Segments AnalyzedEnd-User, Therapeutic Application, Therapy Type, Cell Type
Countries AnalyzedSingapore, Thailand, Japan, China, India, Australia & New Zealand, Singapore, and Rest of Asia-Pacific
Companies Analyzed

Anterogen Co Ltd, Bristol Myers Squibb Company, Cells for Cells SA, Gilead Sciences Inc, JCR Pharmaceuticals Co Ltd, Kolon TissueGene Inc, MEDIPOST Co Ltd, Mesoblast Limited, NuVasive Inc, Smith & Nephew Plc, Stemedica Cell Technologies Inc, Vericel Corporation

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    1. RESEARCH SCOPE & METHODOLOGY
      • STUDY OBJECTIVES
      • SCOPE OF STUDY
      • METHODOLOGY
      • ASSUMPTIONS & LIMITATIONS
    2. EXECUTIVE SUMMARY
      • MARKET SIZE & ESTIMATES
      • MARKET OVERVIEW
    3. MARKET DYNAMICS
      • KEY DRIVERS
        • INCREASING CELLULAR THERAPY CLINICAL TRIALS
        • GROWTH OF REGENERATIVE MEDICINE
        • HIGH PREVALENCE OF CHRONIC DISEASES
      • KEY RESTRAINTS
        • INCREASING SKILLS GAP
        • HIGH COSTS
    1. KEY ANALYTICS
      • IMPACT OF COVID-19 ON CELL THERAPY MARKET
      • KEY MARKET TRENDS
      • PORTER’S FIVE FORCES ANALYSIS
        • BUYERS POWER
        • SUPPLIERS POWER
        • SUBSTITUTION
        • NEW ENTRANTS
        • INDUSTRY RIVALRY
      • REGULATORY FRAMEWORK
      • OPPORTUNITY MATRIX
      • VENDOR LANDSCAPE
    2. MARKET BY CELL TYPE
      • STEM CELL
        • BONE MARROW
        • BLOOD
        • UMBILICAL CORD-DERIVED STEM CELL
        • ADIPOSE-DERIVED STEM CELL
        • OTHERS
      • NON-STEM CELL
    3. MARKET BY THERAPY TYPE
      • AUTOLOGOUS
      • ALLOGENEIC
    4. MARKET BY THERAPEUTIC APPLICATION
      • MALIGNANCIES
      • MUSCULOSKELETAL DISORDERS
      • AUTOIMMUNE DISORDERS
      • DERMATOLOGY
      • OTHER APPLICATIONS
    5. MARKET BY END-USER
      • HOSPITALS & CLINICS
      • ACADEMIC & RESEARCH INSTITUTES
    6. GEOGRAPHICAL ANALYSIS
      • ASIA-PACIFIC
        • MARKET SIZE & ESTIMATES
        • KEY DRIVERS
        • KEY CHALLENGES
        • KEY PLAYERS
        • COUNTRY ANALYSIS
          • CHINA
          • JAPAN
          • INDIA
          • SOUTH KOREA
          • THAILAND
          • SINGAPORE
          • AUSTRALIA & NEW ZEALAND
          • REST OF ASIA-PACIFIC
    1. COMPETITIVE LANDSCAPE
      • KEY STRATEGIC DEVELOPMENTS
        • MERGERS & ACQUISITIONS
        • PRODUCT LAUNCHES & DEVELOPMENTS
        • PARTNERSHIPS & AGREEMENTS
        • BUSINESS EXPANSIONS
      • COMPANY PROFILES
        • ANTEROGEN CO LTD
        • BRISTOL MYERS SQUIBB COMPANY
        • CELLS FOR CELLS SA
        • GILEAD SCIENCES INC
        • JCR PHARMACEUTICALS CO LTD
        • KOLON TISSUEGENE INC
        • MEDIPOST CO LTD
        • MESOBLAST LIMITED
        • NUVASIVE INC
        • SMITH & NEPHEW PLC
        • STEMEDICA CELL TECHNOLOGIES INC
        • VERICEL CORPORATION

    LIST OF TABLES

    TABLE 1: MARKET SNAPSHOT – CELL THERAPY

    TABLE 2: REGULATORY FRAMEWORK

    TABLE 3: ASIA-PACIFIC CELL THERAPY MARKET, BY CELL TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 4: ASIA-PACIFIC CELL THERAPY MARKET, BY CELL TYPE, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 5: ASIA-PACIFIC CELL THERAPY MARKET, BY STEM CELL, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 6: ASIA-PACIFIC CELL THERAPY MARKET, BY STEM CELL, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 7: ASIA-PACIFIC CELL THERAPY MARKET, BY THERAPY TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 8: ASIA-PACIFIC CELL THERAPY MARKET, BY THERAPY TYPE, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 9: ASIA-PACIFIC CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 10: ASIA-PACIFIC CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 11: ASIA-PACIFIC CELL THERAPY MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 12: ASIA-PACIFIC CELL THERAPY MARKET, BY END-USER, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 13: ASIA-PACIFIC CELL THERAPY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 14: ASIA-PACIFIC CELL THERAPY MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 15: KEY PLAYERS IN ASIA-PACIFIC CELL THERAPY MARKET

    TABLE 16: LIST OF MERGERS & ACQUISITIONS

    TABLE 17: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

    TABLE 18: LIST OF PARTNERSHIPS & AGREEMENTS

    TABLE 19: LIST OF BUSINESS EXPANSIONS

    LIST OF FIGURES

    FIGURE 1: KEY MARKET TRENDS

    FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

    FIGURE 3: OPPORTUNITY MATRIX

    FIGURE 4: VENDOR LANDSCAPE

    FIGURE 5: ASIA-PACIFIC CELL THERAPY MARKET, GROWTH POTENTIAL, BY CELL TYPE, IN 2021

    FIGURE 6: ASIA-PACIFIC CELL THERAPY MARKET, BY STEM CELL, 2022-2030 (IN $ MILLION)

    FIGURE 7: ASIA-PACIFIC CELL THERAPY MARKET, GROWTH POTENTIAL, BY STEM CELL, IN 2021

    FIGURE 8: ASIA-PACIFIC CELL THERAPY MARKET, BY BONE MARROW, 2022-2030 (IN $ MILLION)

    FIGURE 9: ASIA-PACIFIC CELL THERAPY MARKET, BY BLOOD, 2022-2030 (IN $ MILLION)

    FIGURE 10: ASIA-PACIFIC CELL THERAPY MARKET, BY UMBILICAL CORD-DERIVED STEM CELL, 2022-2030 (IN $ MILLION)

    FIGURE 11: ASIA-PACIFIC CELL THERAPY MARKET, BY ADIPOSE-DERIVED STEM CELL, 2022-2030 (IN $ MILLION)

    FIGURE 12: ASIA-PACIFIC CELL THERAPY MARKET, BY OTHERS, 2022-2030 (IN $ MILLION)

    FIGURE 13: ASIA-PACIFIC CELL THERAPY MARKET, BY NON-STEM CELL, 2022-2030 (IN $ MILLION)

    FIGURE 14: ASIA-PACIFIC CELL THERAPY MARKET, GROWTH POTENTIAL, BY THERAPY TYPE, IN 2021

    FIGURE 15: ASIA-PACIFIC CELL THERAPY MARKET, BY AUTOLOGOUS, 2022-2030 (IN $ MILLION)

    FIGURE 16: ASIA-PACIFIC CELL THERAPY MARKET, BY ALLOGENEIC, 2022-2030 (IN $ MILLION)

    FIGURE 17: ASIA-PACIFIC CELL THERAPY MARKET, GROWTH POTENTIAL, BY THERAPEUTIC APPLICATION, IN 2021

    FIGURE 18: ASIA-PACIFIC CELL THERAPY MARKET, BY MALIGNANCIES, 2022-2030 (IN $ MILLION)

    FIGURE 19: ASIA-PACIFIC CELL THERAPY MARKET, BY MUSCULOSKELETAL DISORDERS, 2022-2030 (IN $ MILLION)

    FIGURE 20: ASIA-PACIFIC CELL THERAPY MARKET, BY AUTOIMMUNE DISORDERS, 2022-2030 (IN $ MILLION)

    FIGURE 21: ASIA-PACIFIC CELL THERAPY MARKET, BY DERMATOLOGY, 2022-2030 (IN $ MILLION)

    FIGURE 22: ASIA-PACIFIC CELL THERAPY MARKET, BY OTHER APPLICATIONS, 2022-2030 (IN $ MILLION)

    FIGURE 23: ASIA-PACIFIC CELL THERAPY MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021

    FIGURE 24: ASIA-PACIFIC CELL THERAPY MARKET, BY HOSPITALS & CLINICS, 2022-2030 (IN $ MILLION)

    FIGURE 25: ASIA-PACIFIC CELL THERAPY MARKET, BY ACADEMIC & RESEARCH INSTITUTES, 2022-2030 (IN $ MILLION)

    FIGURE 26: ASIA-PACIFIC CELL THERAPY MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

    FIGURE 27: CHINA CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 28: JAPAN CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 29: INDIA CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 30: SOUTH KOREA CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 31: THAILAND CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 32: SINGAPORE CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 33: AUSTRALIA & NEW ZEALAND CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 34: REST OF ASIA-PACIFIC CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)       

    1. GEOGRAPHICAL ANALYSIS
      • ASIA-PACIFIC
        • MARKET SIZE & ESTIMATES
        • KEY DRIVERS
        • KEY CHALLENGES
        • KEY PLAYERS
        • COUNTRY ANALYSIS
          • CHINA
          • JAPAN
          • INDIA
          • SOUTH KOREA
          • THAILAND
          • SINGAPORE
          • AUSTRALIA & NEW ZEALAND
          • REST OF ASIA-PACIFIC
    1. MARKET BY CELL TYPE
      • STEM CELL
        • BONE MARROW
        • BLOOD
        • UMBILICAL CORD-DERIVED STEM CELL
        • ADIPOSE-DERIVED STEM CELL
        • OTHERS
      • NON-STEM CELL
    2. MARKET BY THERAPY TYPE
      • AUTOLOGOUS
      • ALLOGENEIC
    3. MARKET BY THERAPEUTIC APPLICATION
      • MALIGNANCIES
      • MUSCULOSKELETAL DISORDERS
      • AUTOIMMUNE DISORDERS
      • DERMATOLOGY
      • OTHER APPLICATIONS
    4. MARKET BY END-USER
      • HOSPITALS & CLINICS
      • ACADEMIC & RESEARCH INSTITUTES

    To request a free sample copy of this report, please complete the form below :

    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type